Viewing Study NCT05664061

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 12:35 PM

Ignite Modification Date: 2025-12-27 @ 9:29 PM

Study NCT ID: NCT05664061

Status: UNKNOWN

Last Update Posted: 2023-03-01

First Post: 2022-12-15

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Sponsor: Respirent Pharmaceuticals Co Ltd.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module